Please assess the completion status of the following clinical trial:

Trial Title: PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients at least 18 years of age~2. Patients with AK lesions within a contiguous 25 cm2 area on the upper extremity~3. Patients with a 25 cm2 area of normal skin on the upper inner arm~4. Female subjects must be of either non-childbearing potential or childbearing potential, provided there is a confirmed negative urine pregnancy test prior to exposure, to rule out pregnancy~5. Female subjects of childbearing potential must be willing to consent to using high effective methods of contraception~6. Ability to follow study instructions and likely to complete all study requirements~7. Obtained written informed consent prior to any study-related procedures~Exclusion Criteria:~1. Location of the selected treatment areas within 5 cm of an incompletely healed wound within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~2. History or evidence of skin conditions other than the study indication that would interfere with evaluation of the study medication~3. Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety, as determined by Investigator clinical judgment.~4. Anticipated need for in-patient hospitalisation or in-patient surgery during the study period.~5. Current participation in any other interventional clinical trial~6. Subjects who have received treatment with any non-marketed drug product within the last two months~7. Subject known or, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol~8. Females who are pregnant, of child-bearing potential and wishing to become pregnant during the trial, or are breast feeding~9. Undergone cosmetic or therapeutic procedures within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit~10. Use of acid-containing therapeutic products within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit~11. Use of topical salves/topical steroids: within 2 cm of the selected treatment areas in the 2 weeks prior to the screening visit~12. Treatment with immunomodulators, cytotoxic drugs or interferon/interferon inducers, systemic medications that suppress the immune system or UVB in the last 4 weeks~13. Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 2 cm of the selected treatment areas within 8 weeks prior to any screening visit~14. Use of systemic retinoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ingenol mebutate (Type: EXPERIMENTAL): PEP gel 0.05% once daily exposure

Based on this trial design, predict the completion outcome and termination type (if applicable).